Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Insmed’s iPlex Gets Updated User Fee Date Of Dec. 12

This article was originally published in The Pink Sheet Daily

Executive Summary

Insmed's NDA for the growth therapy iPlex (mecasermin rinfibate) has an updated user fee date of Dec. 12, the firm announced Oct. 25

You may also be interested in...



Insmed iPlex Growth Agent “Approvable” Letter Leaves Orphan Status Issue Open

Exclusivity discussions with Office of Orphan Products Development are ongoing, CEO Geoffrey Allan says Sept. 28; letter requests chemistry, manufacturing and controls data.

Tercica’s Growth Treatment Increlex Clears FDA With Orphan Drug Exclusivity

The company plans to launch the extreme short stature therapy in January with a 30-member sales force.

Cancer-Genomics Firm Quanticel Debuts With Close Ties To Celgene, And An Exit In Mind

Celgene will get exclusive use of Quanticel's single-cell genomic analysis to tweak its clinical pipeline, and it also has exclusive options to acquire the venture-backed start-up.

Topics

UsernamePublicRestriction

Register

PS061159

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel